Establishing the Salience of Type 1 Interferon Pathway Blockade in the Central Mechanisms of SLE Related Fatigue
Not yet recruitingOBSERVATIONAL
Enrollment
20
Participants
Timeline
Start Date
March 17, 2025
Primary Completion Date
March 17, 2025
Study Completion Date
March 15, 2027
Conditions
Systemic Lupus Erythematosus
Interventions
DRUG
Anifrolumab
Anifrolumab 300mg intravenous infusions administered as described in the EU SmPC
All Listed Sponsors
lead
NHS Greater Glasgow and Clyde
OTHER
NCT06784076 - Establishing the Salience of Type 1 Interferon Pathway Blockade in the Central Mechanisms of SLE Related Fatigue | Biotech Hunter | Biotech Hunter